What is Monte Rosa Therapeutics, Inc.'s interest coverage?

Monte Rosa Therapeutics, Inc. (GLUE) reported interest coverage of -9.8× in Q1 2026.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s interest coverage?

Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s interest coverage has grown at a -86.2% compound annual growth rate (CAGR), from -1,584.4× to -4.2×.

What does interest coverage mean?

Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.

Monte Rosa Therapeutics, Inc. GLUE Interest coverage

Interest coverage at other companies

Cogent Biosciences, Inc.COGT

-84.7×—

Adaptive BiotechnologiesADPT

-4×-1.6×

Arcus BiosciencesRCUS

-39.8×-15.5×

Viridian Therapeutics, Inc.VRDN

-49.3×-20.0×

IncyteINCY

689.3×+620×

Immunovant, Inc.IMVT

-19×+5.0×

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

ebit/interest expense=-9.8×

Based on trailing twelve months.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s interest coverage?: Monte Rosa Therapeutics, Inc. (GLUE) reported interest coverage of -9.8× in Q1 2026.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s interest coverage?: Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s interest coverage has grown at a -86.2% compound annual growth rate (CAGR), from -1,584.4× to -4.2×.
What does interest coverage mean?: Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.